Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

iverables under our agreement. We currently expect this performance period to end in the fourth quarter of 2012.

Research and development expenses for the three and six months ended June 30, 2010 were $3.1 million and $9.5 million, respectively, compared to $3.6 million and $5.3 million, respectively, in the corresponding periods of 2009. The increased research and development expenses recorded in the six months ended June 30, 2010 are the result of increased expenses relating to OncoGenex's contribution to the custirsen Phase 3 clinical trials. The lower research and development expenses in the second quarter of 2010 as compared with the second quarter of 2009 are the result of a $0.5 million non-cash expense included in research and development expenses in the second quarter of 2009.

General and administrative expenses for the three and six months ended June 30, 2010 were $1.5 million and $2.8 million, respectively, compared to $1.0 million and $1.8 million, respectively, in the corresponding periods of 2009. The increases in 2010 were due mainly to higher employee expenses including severance charges, professional fees for legal and accounting services, employee recruitment costs and stock based compensation expense.

An income tax recovery of $3.0 million was recorded in the second quarter of 2010, as the Company received approval from the Israel Tax Authority (ITA) for its request for a withholdings tax exemption on amounts received from Teva in relation to the Collaboration Agre
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... TRIANGLE PARK, N.C. , May 1, 2015  United ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer of ... company,s business at the Deutsche Bank 40 th Annual ... The presentation will take place on Wednesday, May ... accessed via a live webcast on the United Therapeutics website ...
(Date:4/30/2015)... --  Tamir Biotechnology , a leading developer of RNA ... antiviral therapy program. Clinical Progress ... evaluated and considered by a number of clinicians on ... first quarter of 2015, the company participated in the ... of Potential Treatments and Vaccines For Ebola In West ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Nitto ... today announces its increased capacity and production capability ... increased client variety and service fulfillment continues to ... improve process throughput capacities. , ... newly installed downstream process equipment at its Milford, ...
(Date:4/30/2015)... Hungary (PRWEB) April 30, 2015 ... lab notebook with integrated protocols and specimen management ... software solutions and consulting services for life science ... development of Labguru’s newest feature: chemical structure and ... domain features for biologists, bio-chemists, and more, the ...
Breaking Biology Technology:Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... a simple, single-step process, engineers and scientists at ... a technique to direct benign, filamentous viruses called ... for materials with a wide range of properties. ... researchers caused the viruses to self-assemble into hierarchically ...
... and scientists from Reproductive Medicine Associates of New ... groundbreaking research study entitled Cleavage Stage Embryo ... Biopsy Does Not: A Novel Paired Analysis of ... study, led by Richard T. Scott, M.D. and ...
... Process automation specialist Endress+Hauser has acquired a stake in ... distributes sensors, hardware and software for bioprocess engineering. ... the area of biotechnology through this cooperation. "Biotechnological procedures ... not only in the life sciences industry but also ...
Cached Biology Technology:Manufacturing goes viral 2Manufacturing goes viral 3Manufacturing goes viral 4Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Dec 03, 2010, Seoul, S. Korea Institut Pasteur ... & Development of Toulouse, France to continue research on ... agreement drawn up in the fall of 2009, illustrates ... The technology platform will be used to pinpoint active, ...
... of the most promising technological research projects at University ... of federal cash to help them through the most ... commercial market. With $5.1 million in federal funding, ... of Maryland research institutions and the U.S. Army Research ...
... has just released the first issue of its newest ... JIPM ), which is available online for free. ... that covers the field of integrated pest management. The ... is engaged in any aspect of integrated pest management, ...
Cached Biology News:$5.1 million Army-Md. alliance speeds university research to market 2$5.1 million Army-Md. alliance speeds university research to market 3$5.1 million Army-Md. alliance speeds university research to market 4$5.1 million Army-Md. alliance speeds university research to market 5Journal of Integrated Pest Management is now online 2
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Biology Products: